MRI Right Before or After Surgery Does Not Benefit Women with Early Breast Cancer

Released: 4-Sep-2013 1:30 PM EDT
Embargo expired: 4-Sep-2013 5:00 PM EDT
Source Newsroom: Memorial Sloan Kettering Cancer Center
Contact Information

Available for logged-in reporters only

Citations 2013 Breast Cancer Symposium

Newswise — NEW YORK, September 4, 2013 — A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates. The findings are being presented on Saturday, September 7, 2013, at the 2013 Breast Cancer Symposium.

While no clinical practice guidelines exist for the use of MRI around the time of surgery, some surgeons use the screening tool to obtain a clearer picture of the cancer before surgery is performed or immediately after surgery to check for any residual disease. Previous studies have shown that using MRI in this capacity for women with invasive breast cancer does not have a clinically significant impact on local recurrence or contralateral breast cancer rates; however, the impact on women with DCIS is not well studied.

“MRI use varies widely by institution and surgeon preference,” said Melissa L. Pilewskie, MD, first study author and breast surgeon at Memorial Sloan-Kettering. “MRI is an expensive test with a high false-positive rate that can lead to additional and sometimes unnecessary procedures, so its use should be examined carefully. These findings add to the growing list of evidence that suggests that MRI does not provide a clear benefit for DCIS patients.”

Researchers identified 2,321 women who had had breast-conserving surgery for DCIS between 1997 and 2010 at Memorial Sloan-Kettering. Of these patients, 596 had received an MRI either before or immediately after surgery and 1,725 had not. The rates of local recurrence and contralateral breast cancer were compared at the five-year and eight-year mark in each group.

After five years, local recurrence rates were not significantly different between the two groups (8.5 percent with MRI vs. 7.2 percent without MRI). Similarly, eight-year recurrence rates were not significantly different (14.6 percent vs. 10.2 percent). Even after controlling for nine other patient variables such as age and menopausal status, no difference in risk of local recurrence was seen. Results also showed that there was no statistically significant difference in contralateral breast cancer rates (3.5 percent vs. 3.5 percent at five years and 3.5 percent vs. 5.1 percent at eight years).

Dr. Pilewskie also stressed that not all women with DCIS receive radiation therapy, which is often used to reduce recurrence rates after breast-conserving surgery. Yet, even in the subgroup of patients who did not receive radiation therapy, MRI was not associated with improved long-term outcomes for these women.

# # #

About Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center is the world’s oldest and largest private cancer center with more than 125 years devoted to exceptional patient care, innovative research, and outstanding educational programs. We are one of 41 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment.

The close collaboration between physicians and scientists enables Memorial Sloan-Kettering to provide patients with the best care available as they work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan-Kettering has an impact on cancer treatment and biomedical research around the world. For more information, go to www.mskcc.org.


Comment/Share